Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza CandidatesBenzinga • 04/05/21
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of InfluenzaGlobeNewsWire • 04/05/21
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/25/21
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical OperationsGlobeNewsWire • 12/15/20
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza ConferenceGlobeNewsWire • 12/01/20
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020GlobeNewsWire • 11/30/20
Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/06/20
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/05/20
Analysts Estimate Cidara Therapeutics (CDTX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/29/20
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020GlobeNewsWire • 10/21/20
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020GlobeNewsWire • 09/14/20
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial ResultsGlobeNewsWire • 08/13/20
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/20
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral TherapeuticsGlobeNewsWire • 07/17/20
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19GlobeNewsWire • 06/23/20
Cidara Therapeutics to Present at the Raymond James Human Health Innovations ConferenceGlobeNewsWire • 06/11/20
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow TransplantationGlobeNewsWire • 05/20/20
Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/13/20
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial ResultsGlobeNewsWire • 05/13/20
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)GlobeNewsWire • 05/05/20